Please provide your email address to receive an email when new articles are posted on . The angiotension receptor blocker candesartan has demonstrated the ability to significantly regress diabetic ...

The aim of the present study was to investigate the pharmacokinetics and short-term tolerability of the angiotensin II type 1 receptor antagonist candesartan cilexetil in patients receiving ...

Treatment with candesartan can increase regression of retinopathy in type 2 diabetes and reduce incidence of retinopathy in type 1 diabetes. These are among the conclusions of the DIRECT studies ...

On the other hand, the randomised evaluation of strategies of left ventricular dysfunction (RESOLVD) study showed that another AII receptor antagonist, candesartan, appears to be comparable with ...

Bilous and colleagues report that treatment with the angiotensin-receptor blocker candesartan does not prevent microalbuminuria in patients with type 1 or type 2 diabetes mellitus who are ...

In a comparison of the angiotensin II receptor blockers (ARBs) candesartan and losartan, used by patients with heart failure, candesartan was associated with a lower risk of death at 1 and 5 years ...

To determine whether the pharmacological characteristics of candesartan offer advantages over the first in class ARB, losartan, with respect to anti-hypertensive efficacy, we undertook a meta ...